Twist Bioscience price target raised to $54 from $50 at Scotiabank

Scotiabank raised the firm’s price target on Twist Bioscience (TWST) to $54 from $50 and keeps an Outperform rating on the shares. The company wrapped up FY24 on a strong note, beating consensus and guidance across the board, the analyst tells investors. Looking ahead, the firm expects the company to remain well-positioned to continue to outperform its peer group across multiple macro scenarios.